|
|
Article: BIOGEN IDEC/JOHNS HOPKINS TO DEVELOP NEURODEGENERATIVE THERAPIES.
- Article from:
- Biotech Business
- Article date:
- November 1, 2007
CopyrightCOPYRIGHT 2007 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Biogen Idec (NASDAQ: BIIB), Cambridge, Mass, has announced a research collaboration with the newly formed Brain Science Institute at Johns Hopkins University to discover and develop therapies for neurodegenerative diseases such as multiple sclerosis, Alzheimer's and Parkinson's. The collaboration, the first of its kind between Biogen Idec and the University, will be focused on discovering and advancing clinical candidates from the lab into the clinic, with an emphasis on discovering new therapeutics for these diseases.
"Johns Hopkins is home to over 600 staff members and scientists who are focused on the neurosciences, offering world-class expertise in the ...